Proposed US legislation aimed at patent thickets unlikely to boost biologics competition
The Biologic Patent Transparency Act seeks to accelerate biosimilar entry, but leaves key litigation issues unaddressed and would confer only marginal benefits on imitators
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10